论文部分内容阅读
1977～1982年在维也纳第一及第二大学妇科医院用转移因子对浸润性宫颈癌作辅助性免疫治疗。制备转移因子的白细胞均由患者丈夫提供。治疗分两组进行,一组给予转移因子,一组用安慰剂。病人年龄和分期都相似,以双育法进行随机分组研究。治疗在根治术3周后开始(在术后放疗开始之前),每月皮下注射转移因子2U,整个疗程持续2年。并未发现严重的并发症,病人主观上对注射耐受也很好,每3个月进行一次临床及免疫学检查。共治疗60例,32例用转移因子治疗,28例用安慰剂。32例接受转移因子组中有1例在术后死于其它疾病,按统计学规定分析时不包括此例。在治疗组中有5例复发,而安慰剂组中有11例复发。统计学差异明显(P<0.05)。出现复发的时间也有明显不同:在治疗组均为术后7个月,安慰
1977-1982 in Vienna, the first and second university gynecological hospital with transfer factor for invasive cervical cancer for adjuvant immunotherapy. Leukocytes prepared for transfer factor are provided by the patient’s husband. Treatment was divided into two groups, one for the transfer factor, one for the placebo. Patients were similar in age and staging, and were randomized to double-parent study. Treatment started 3 weeks after radical surgery (before the start of postoperative radiotherapy), subcutaneous injection of transfer factor 2U per month, the entire course of treatment for 2 years. No serious complications were found and patients were subjectively tolerant of injections. Clinical and immunologic tests were performed every 3 months. A total of 60 cases of treatment, 32 cases with transfer factor treatment, 28 cases with placebo. One of the 32 patients who received the transfer factor died of other diseases after surgery, which was not included in the analysis as a statistic. Five patients relapsed in the treatment group and 11 in the placebo group. Statistical difference was significant (P <0.05). Recurrence of the time there are also significantly different: in the treatment group were 7 months after surgery, comfort